Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

anding (000's) - basic and diluted 85,118 85,118 ------------------------------------------------------------------------- ------------------------------------------------------------------------- (in thousands of U.S.$, except Year ended share and per share data) December 31, 2007 ------------------------------------------------------------------------- Reported Adjustments Adjusted REVENUE Royalty revenue $ 116,659 $ - $ 116,659 Product sales, net 170,193 2,579 a 172,772 License fees 842 (842) b - ------------------------------------------------------------------------- 287,694 1,737 289,431 ------------------------------------------------------------------------- EXPENSES License and royalty fees 18,652 - 18,652 Cost of products sold 94,949 (2,065) c 92,884 Research and development 53,963 (4,582) d 49,381 Selling, general and administrative 99,315 (16,470) e 82,845 Depreciation and amortization 33,429 (29,971) f 3,458 In-process research and development 8,125 (8,125) g - ------------------------------------------------------------------------- 308,433 (61,213) 247,220 ------------------------------------------------------------------------- Operating (loss) income (20,739) 62,950 42,211 ------------------------------------------------------------------------- Other income (expenses): Foreign exchange gain (loss) (
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... In a video interview, new CEO,Andrew Witty comments on ... strategic vision for the business., The ... diversified global business - Deliver more products of value ... and vodcast are available now on, http://www.cantos.com . It,s free ...
... 23 Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ... a synopsis of a proposed Phase 3 clinical ... Food and Drug Administration,s (the,"FDA") Division of Cardiovascular ... with the FDA, including a face-to-face,meeting held on ...
... Next generation design reduces the amount of retraction needed for surgical ... ... July 23 Pioneer Surgical Technology,today announces the market availability of ... optimize,anterior cervical fusion procedures while addressing the clinical needs of,anterior cervical ...
Cached Biology Technology:Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2
(Date:4/18/2014)... predicted to reach 9 billion by 2050 will ... human-altered landscapes such as farmland, according to Stanford ... supports it might be an increasingly scarce commodity ... the land surface is directly affected by humans ... such as climate change. But what if altered ...
(Date:4/18/2014)... comet impacts can cause widespread ecological havoc, killing off ... But new research from Brown University shows that impacts ... the time of an impact. , A research team ... of leaves and preserved organic compounds lodged inside glass ... material could provide a snapshot of environmental conditions at ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... and Wireless ... Solutions for Emergency Responders, WALL, N.J., Oct. 15 ... biometric,identification and wireless public safety solutions, today announced that,it will ... of Chiefs of Police (IACP) Conference and,Exposition, October 15-17 at ...
... early in adulthood, aging begins to slow the mind,s growth ... suggests a Princeton University study on the brains of adult ... soon after marmoset monkeys reach adulthood, the rate at which ... animals, brains begins to decline. The hippocampus is associated with ...
... (AD) is a progressive neurodegenerative disorder characterized by ... amyloid plaques and neurofibrillary tangles. Neuronal and synaptic ... occur in specific brain areas involved in memory ... cerebral deposition of A" plays a seminal role ...
Cached Biology News:BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 2BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 3Brain cell growth diminishes long before old age strikes, animal study shows 2Paradigm shift in Alzheimers's research: new treatments 2Paradigm shift in Alzheimers's research: new treatments 3Paradigm shift in Alzheimers's research: new treatments 4
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
X-gal,1g...
...
Biology Products: